Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs).
Authors:
- Georges GebraelGGGeorges Gebrael
- Nicolas SayeghNSNicolas Sayegh
- Nishita TripathiNTNishita Tripathi
- Divyam GoelDGDivyam Goel
- James BrundageJBJames Brundage
- Taylor Ryan McFarlandTMTaylor Ryan McFarland
- Blake NordbladBNBlake Nordblad
- Beverly ChigariraBCBeverly Chigarira
- Vinay Mathew ThomasVTVinay Mathew Thomas
- Kamal Kant SahuKSKamal Kant Sahu
- Haoran LiHLHaoran Li
- 1 June 2023
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (16_suppl) , 5049
Abstract
No abstract availableKeywords
Funding Information
- None.